Bilthoven Biologicals

Executive Summary

Bilthoven Biologicals, a subsidiary of the Cyrus Poonawalla Group and Serum Institute of India, is a global vaccine manufacturer headquartered in the Netherlands with a rich legacy dating back to 1909. The company is dedicated to accelerating access to vaccines and biologicals against infectious diseases, operating with the mission that health is a human right. It serves over 90 countries, supplying essential vaccines for public health programs worldwide. As part of the world's largest vaccine manufacturer by volume, Bilthoven Biologicals leverages its parent company's scale and expertise while maintaining its own manufacturing and development capabilities. The company focuses on producing high-quality, affordable vaccines to address global health challenges, including polio, influenza, and other infectious diseases. With a strong commitment to innovation and global health equity, Bilthoven Biologicals is well-positioned to support immunization programs in low- and middle-income countries, contributing to the elimination of vaccine-preventable diseases. Its strategic location in Europe provides access to advanced manufacturing technologies and regulatory pathways, enhancing its ability to develop and distribute critical vaccines rapidly. The company's long-standing partnerships with international health organizations and governments underscore its reliability and impact in the global vaccine landscape.

Upcoming Catalysts (preview)

• Q3 2026Polio Vaccine Supply Agreement with UNICEF80% success
• H2 2026Completion of New Manufacturing Facility Expansion for Influenza Vaccines70% success
• Q4 2026Strategic Partnership with Gavi for Vaccine Distribution in Africa60% success